General Info

Oncologic was founded in January 2000 to pioneer the development of a scientific breakthrough for the treatment of cancers. The approach is called S.T.A.R., which stands for Selectively Targeted Amplified Radiotherapy. The center of the S.T.A.R. advantage is a powerful nanotechnology that unites advances in molecular biology, proteomics and chemotherapeutics into a different intravenous therapy sequence that burns out primary and metastatic tumors by delivering and immobilizing radioisotopes, without significant damage to normal cells and tissues. Oncologic s S.T.A.R. is modeled on the 95-percent curative therapy of thyroid cancer with radioactive iodine and applies the same therapeutic strategy to most other cancers.